Pathological autoantibody internalisation in myositis.

Antibodies Autoantibodies Dermatomyositis Polymyositis

Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
20 Jun 2024
Historique:
received: 06 03 2024
accepted: 11 06 2024
medline: 21 6 2024
pubmed: 21 6 2024
entrez: 20 6 2024
Statut: aheadofprint

Résumé

Autoantibodies targeting intracellular proteins are common in various autoimmune diseases. In the context of myositis, the pathologic significance of these autoantibodies has been questioned due to the assumption that autoantibodies cannot enter living muscle cells. This study aims to investigate the validity of this assumption. Confocal immunofluorescence microscopy was employed to localise antibodies and other proteins of interest in myositis muscle biopsies. Bulk RNA sequencing was used to examine the transcriptomic profiles of 669 samples, including those from patients with myositis, disease controls and healthy controls. Additionally, antibodies from myositis patients were introduced into cultured myoblasts through electroporation, and their transcriptomic profiles were analysed using RNA sequencing. In patients with myositis autoantibodies, antibodies accumulated inside myofibres in the same subcellular compartment as the autoantigen. Bulk RNA sequencing revealed that muscle biopsies from patients with autoantibodies targeting transcriptional regulators exhibited transcriptomic patterns consistent with dysfunction of the autoantigen. For instance, in muscle biopsies from patients with anti-PM/Scl autoantibodies recognising components of the nuclear RNA exosome complex, an accumulation of divergent transcripts and long non-coding RNAs was observed; these RNA forms are typically degraded by the nuclear RNA exosome complex. Introducing patient antibodies into cultured muscle cells recapitulated the transcriptomic effects observed in human disease. Further supporting evidence suggested that myositis autoantibodies recognising other autoantigens may also disrupt the function of their targets. This study demonstrates that, in myositis, autoantibodies are internalised into living cells, causing biological effects consistent with the disrupted function of their autoantigen.

Identifiants

pubmed: 38902010
pii: ard-2024-225773
doi: 10.1136/ard-2024-225773
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Iago Pinal-Fernandez (I)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Sandra Muñoz-Braceras (S)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Maria Casal-Dominguez (M)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Katherine Pak (K)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Jiram Torres-Ruiz (J)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Jon Musai (J)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Stefania Dell'Orso (S)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Faiza Naz (F)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Shamima Islam (S)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Gustavo Gutierrez-Cruz (G)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Maria Dolores Cano (MD)

Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.

Ana Matas-Garcia (A)

Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
Barcelona University, Barcelona, Spain.
CIBERER and IDIBAPS, Barcelona, Spain.

Joan Padrosa (J)

CIBERER and IDIBAPS, Barcelona, Spain.

Ester Tobias-Baraja (E)

Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
Barcelona University, Barcelona, Spain.
CIBERER and IDIBAPS, Barcelona, Spain.

Gloria Garrabou (G)

Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
Barcelona University, Barcelona, Spain.
CIBERER and IDIBAPS, Barcelona, Spain.

Iban Aldecoa (I)

Pathology, Neurological Tissue Bank, Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain.

Gerard Espinosa (G)

Barcelona University, Barcelona, Spain.
Department of Autoimmune Diseases, Reference Centre for Systemic Autoimmune Diseases (UEC/CSUR) of the Catalan and Spanish Health Systems-Member of ERN-ReCONNET, Hospital Clinic, Barcelona, Spain.

Carmen Pilar Simeon-Aznar (CP)

Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.

Alfredo Guillen-Del-Castillo (A)

Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.

Albert Gil-Vila (A)

Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.

Ernesto Trallero-Araguás (E)

Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.
Rheumatology Department, Vall d'Hebron Hospital, Barcelona, Spain.

Lisa Christopher-Stine (L)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Thomas E Lloyd (TE)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Teerin Liewluck (T)

Division of Neuromuscular Medicine, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Elie Naddaf (E)

Division of Neuromuscular Medicine, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Werner Stenzel (W)

Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.

Steven A Greenberg (SA)

Department of Neurology, Brigham and Women's Hospital and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Josep Maria Grau (JM)

Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
Barcelona University, Barcelona, Spain.
CIBERER and IDIBAPS, Barcelona, Spain.

Albert Selva-O'Callaghan (A)

Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain.
Autonomous University of Barcelona, Barcelona, Spain.

Jose Cesar Milisenda (JC)

Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain.
Barcelona University, Barcelona, Spain.
CIBERER and IDIBAPS, Barcelona, Spain.

Andrew Lee Mammen (AL)

Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA andrew.mammen@nih.gov iago.pinalfernandez@nih.gov.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Classifications MeSH